Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The do's and don'ts for drug makers under EMA trial data publication policy

This article was originally published in SRA

Executive Summary

As the European Medicines Agency prepares to implement its policy on the proactive publication of clinical trial data, it is bracing itself for the inevitable disputes with pharmaceutical companies on what constitutes commercially confidential information in a clinical study report and should, therefore, not be made public.

Advertisement

Related Content

EMA Appeals Interim EU Court Orders Preventing Access To Documents
Advertisement
UsernamePublicRestriction

Register

PS118291

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel